Genetic Testing: Algorithmic Testing
This policy addressed gene expression profiling
|
New* |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
*Replaces multiple Medica coverage policies addressing gene expression profiling.
Addresses many additional gene expression profiling tests. |
Genetic Testing: Cancer Screening
This policy addresses genetic marker testing for colorectal and lung cancer screening tests
|
New |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
N/A
|
Genetic Testing: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) |
New* |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
*Replaces former Medica coverage policy, Liquid Biopsy: Testing of Circulating Tumor Cells or Cell-Free Tumor DNA |
Genetic Testing: Cytogenetic Testing
This policy addresses FISH and PCR technologies for classification of solid cell tumors and hematologic malignancies
|
New* |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
* Replaces former Medica coverage policy, Bladder Cancer Screening, Diagnosis and Monitoring using Ancillary Urinary Tests
Addresses many additional cytogenetic tests.
|
Genetic Testing: Hereditary Cancer Susceptibility
This policy addresses genetic testing for germline mutations, including single gene and panel testing
|
New* |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
*Replaces former Medica coverage policy, TP53 (p53) Testing for Li-Fraumeni Syndrome
Addresses many additional hereditary cancer susceptibility tests.
|
Genetic Testing: Molecular Analysis of Solid Tumors and Hematologic Malignances
This policy addresses genetic testing for somatic mutations, including single gene and panel testing
|
New |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
N/A |
Genetic Testing: Pharmacogenetics
This policy addresses genetic testing for prediction of response to drug treatment
|
New* |
12/30/2022 |
Covered for some indications; investigative and not covered for other indications. |
*Replaces multiple Medica coverage policies addressing pharmacogenetic testing.
Addresses many additional pharamcogenetic tests.
|
Genetic Testing: Non-Invasive Prenatal Screening (NIPS) |
New* |
12/30/2022 |
Medically necessary for some indications; investigational for all other indications. |
*Replaces former Medica coverage policy, Maternal Plasma Tests for Detection of Cell-free Fetal DNA for Analysis of Chromosomal Aneuploidies.
Criteria for maternal serum screening (e.g., free or total beta-HCG and PAPP-A) has been added.
|
Genetic Testing: Preimplantation Genetic Testing |
New |
12/30/2022 |
Medically necessary for some indications; investigational for all other indications. |
N/A |
Genetic Testing: Prenatal And Preconception Carrier Screening |
New |
12/30/2022 |
Medically necessary for some indications; investigational for all other indications. |
N/A |
Genetic Testing: Prenatal Diagnosis (Via Amniocentesis, Cvs, Or Pubs) And Pregnancy Loss |
New |
12/30/2022 |
Medically necessary for some indications; investigational for all other indications. |
N/A |